Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
No abstract available

MeSH terms

  • Adenine / analogs & derivatives
  • Antiviral Agents / adverse effects
  • Hepatitis B virus / physiology
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Piperidines
  • Retrospective Studies
  • Virus Activation

Substances

  • Antiviral Agents
  • Piperidines
  • ibrutinib
  • Adenine